Instil Bio, Inc. (TIL)
- Previous Close
10.64 - Open
10.41 - Bid --
- Ask --
- Day's Range
10.41 - 10.78 - 52 Week Range
6.08 - 14.00 - Volume
6,463 - Avg. Volume
18,367 - Market Cap (intraday)
69.657M - Beta (5Y Monthly) 1.25
- PE Ratio (TTM)
-- - EPS (TTM)
-24.00 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
27.67
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
instilbio.comRecent News: TIL
Performance Overview: TIL
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TIL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TIL
Valuation Measures
Market Cap
69.66M
Enterprise Value
5.35M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.31
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.04
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.01%
Return on Equity (ttm)
-52.96%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-156.09M
Diluted EPS (ttm)
-24.00
Balance Sheet and Cash Flow
Total Cash (mrq)
151.41M
Total Debt/Equity (mrq)
38.11%
Levered Free Cash Flow (ttm)
-82.27M